Masimo
Maker of FDA-cleared patient monitoring sensors, now a Danaher subsidiary.
On the record
Checkpoint: Danaher names permanent unit CEO and discloses next phase of $125M cost-synergy cuts
The call
Masimo's patents and hospital contracts still hold, but it now runs inside Danaher's cost-cutting machine with no permanent CEO in place.
Masimo makes hospital equipment that measures patients' oxygen levels and other vital signs. The company built its strength on decades of patents, long-term contracts with hospitals, and ongoing sales of replacement parts and sensors, which made it hard for competitors like Medtronic and Philips to displace. But in mid-2026, larger conglomerate Danaher bought Masimo and took it private, replacing its independent leadership and now pushing to cut over $125 million in costs; what matters most now is whether Danaher can keep Masimo's talented engineers and sales force during the restructuring, whether it appoints a permanent leader soon, and whether it successfully sells Masimo products alongside Danaher's other hospital equipment to win bigger contracts.
Why
01
AI pressure: Apple Watch health-sensing algorithms. Apple keeps refining Watch blood-oxygen and vital-sign algorithms despite the 2023 ITC ban, aiming to route around Masimo patents. Could AI do the core job? Unlikely.
02
Bigger players: Philips, GE HealthCare, Medtronic bundled hospital monitors. Rivals push bundled monitoring suites into IDN contracts, pressuring Masimo's standalone device and consumable sales. Could a giant copy it? No, they are blocked.
03
What protects it. Decades of signal-extraction patents, FDA clearances, and 10-year hospital deployments that are costly to rip out.
What would change this call
Danaher names a permanent CEO for the Masimo unit within 12 months. Shows whether Masimo has stable leadership or remains in limbo post-acquisition.
Danaher discloses headcount or R&D cuts beyond the $125M synergy target. Would indicate integration is eroding core engineering capacity, not just overhead.
A major IDN hospital system publicly switches from Masimo to a Philips, GE, or Medtronic bundled monitor. Would confirm incumbents are winning contracts head-to-head against Masimo.
Danaher discloses headcount or R&D cuts beyond the $125M synergy target. Would indicate integration is eroding core engineering capacity, not just overhead.
A major IDN hospital system publicly switches from Masimo to a Philips, GE, or Medtronic bundled monitor. Would confirm incumbents are winning contracts head-to-head against Masimo.
Key numbers
- Danaher bought Masimo for $9.9B
- Healthcare revenue $1.527B, +9.4% YoY
- Headcount fell 11.3% since 2023
Named risks
- No permanent CEO named for Masimo unit after Szyman's June 2026 departure.
- Danaher integration costs ($108M Q2 2026) could disrupt engineering/product functions.
- Bundling pressure from Philips, GE HealthCare, Medtronic squeezing standalone device sales.
- Ongoing litigation tail from Kiani ouster and shareholder investigation alerts.
- Sharp headcount decline (down to ~2,200 healthcare staff by end 2025) risks knowledge loss.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Medtronic (Nellcor) | contesting | Cited as Masimo's most direct pulse-oximetry rival, dated 2026-06-18 |
| Philips | contesting | Market leader in multi-parameter monitoring, but co-developing AI monitoring with Masimo since Sept 2025 |
| GE HealthCare | contesting | Bundles monitors/services/software into single hospital contracts, per 2026 market analysis |
| Apple | losing to | ITC ruling Oct 2023 blocked Apple Watch blood-oxygen import over Masimo patent infringement |
| Shenzhen Mindray | contesting | Value/price competitor especially in APAC per 2023-03-07 market report |
Questions people ask
- Is Masimo profitable in 2026?
- Yes. In Q1 2026 Masimo reported revenue of $403.6M, up 8.5% year over year, with net income of $57.1M, as of the 10-Q filed May 5, 2026. FY2025 healthcare revenue was $1.527B, up 9.4% YoY.
- Who owns Masimo now?
- Danaher Corporation acquired Masimo for $9.9B and delisted it from Nasdaq on June 10, 2026. Masimo now operates as a standalone subsidiary inside Danaher's Diagnostics segment, alongside Radiometer, Leica Biosystems, Cepheid, and Beckman Coulter.
- Has Masimo had layoffs?
- Yes. Masimo laid off 75 people at its Irvine, CA headquarters in January 2025, and total headcount fell from 7,113 (2023) to 6,309 by December 2025, an 11.3% decline, driven by both layoffs and the Sound United divestiture.
- Could AI replace Masimo?
- Unlikely soon. Masimo's moat rests on decades of patented signal-extraction IP, FDA clearances, and hospital workflow lock-in that AI can't easily replicate. Masimo is itself shipping AI: its smartSET opioid-breathing-risk detection got FDA clearance June 22, 2026.
- Who is Masimo's biggest competitor?
- Medtronic, via its Nellcor pulse-oximetry business, is described as Masimo's most direct rival as of June 18, 2026. Philips and GE HealthCare pressure Masimo through bundling multiparameter monitors, while Philips leads the broader multi-parameter vital-signs market.
- Did Masimo beat Apple in court?
- Yes. Masimo won an ITC ruling in October 2023 that resulted in an import ban tied to Apple Watch's blood-oxygen feature, over infringement of Masimo's pulse-oximetry patents, a major win protecting its core signal-extraction IP.
Timeline
- 2026-07-21Danaher reports $108M Q2 acquisition-related costs, targets over $125M cost synergies from Masimo deal
- 2026-06-22FDA clears Masimo's AI-enabled OIRD detection (smartSET) on Radius VSM wearable monitor
- 2026-06-16CEO Katie Szyman steps down days after Danaher acquisition closes
- 2026-06-10Danaher completes $9.9B acquisition, Masimo delisted from Nasdaq
- 2026-02-17Danaher announces plan to acquire Masimo at $180/share cash
- 2025-09-23Masimo completes $350M sale of Sound United consumer-audio unit to Harman International
- 2025-08-07Masimo's 'empty voting' conspiracy claim against founder Joe Kiani dismissed
- 2024-09-20Founder and CEO Joe Kiani ousted after Politan Capital wins proxy fight
- 2023-10-01Masimo wins ITC ruling blocking Apple Watch blood-oxygen feature imports
Revision history
22 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Danaher completes $10B acquisition of Masimo (2026-06-10)
- Masimo Revenue 2012-2026 (2026-03-30)
- Revenue $403.6M, Net income $57.1M, 10-Q Summary (2026-05-05)
- Katie Szyman Steps Down from Masimo (2026-06-16)
- Politan prevails in Masimo proxy fight (2024-09-20)
- Masimo Completes Sale of Consumer Audio Business to HARMAN International (2025-09-23)
- Masimo Number of Employees 2026 (2026-06-29)
- Masimo (MASI) Number of Employees 2007-2025 (2025-12-30)
- Employee Growth Dips at OC Medical Device Makers (2025-04-21)
- FDA clears Masimo wearable monitor to detect opioid-related breathing risk (2026-06-22)
- St. Luke's Marks 10 Years of Innovation with Masimo (2026-07-09)
- Masimo (2026-01-16)